Example: biology
Q11 Step 5 Development and manufacture of drug substances
A CQA is a physical, chemical, biological, or microbiological property or characteris tic that should be within an appropriate limit, range, or distribution to ensure the desired product quality. Potential drug substance CQAs are used to guide process development. The list of potential CQAs can be modified as
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
ATP 3-11.74 CHEMICAL, BIOLOGICAL, RADIOLOGICAL, AND ...
armypubs.army.milAs the Chemical Corps enters its second century of service in the United States Army, it must adapt to new threats and overcome 15 years of atrophy of chemical, biological, radiological, and nuclear (CBRN) skills within the Army that were attributed to operations in counterinsurgency. Throughout that time, the Chemical Corps
BY ORDER OF THE SECRETARY AIR FORCE MANUAL 10-2503 …
static.e-publishing.af.milThis doctrine outlines AF operations in support of a joint service task force or coalition operations. Joint doctrine publications include Joint Publication 3-01, Countering Air and Missile Threats, Joint Publication 3-11, Operations in Chemical, Biological, Radiological, and Nuclear Environments, and Joint Publication 3-40,
JP 3-41, Chemical, Biological, Radiological, and Nuclear ...
www.jcs.mil3-11, Operations in Chemical, Biological, R adiological, and Nuclear Environments; JP 3-27, Homeland Defense; JP 3-28, Defense Support of Civil Authorities; JP 3-29, Foreign Humanitarian Assistance; and JP 3-40, Countering Weapons of Mass Destruction.
The 2003 Iraq War: Operations, Causes, and Consequences
www.lacsc.orgThe 2003 Iraq War: Operations, Causes, and Consequences ... All chemical, biological, and all stocks of agents, all sub-systems and components of all the facilities for research and development, support,and manufacturing facilities related to weapons of mass destruction must be stopped immediately. ...
Biological Entities - European Medicines Agency
www.ema.europa.euoperations that impact critical quality attributes (CQAs) for evaluation in further studies to establish any design space(s) and control strategies applicable over the lifecycle of the drug substance. ... A CQA is a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range ...
Guidance for Filtration and Air-Cleaning Systems to ...
www.cdc.govchemical, biological, or radiological attacks. With U.S. workers and workplaces facing potential hazards associated with chemical, biological, or radiological terrorism, the occupational health and safety dimension of homeland security is iii
ATP 3-37.11 CHEMICAL, BIOLOGICAL, RADIOLOGICAL, …
armypubs.army.milATP 3-37.11 is written for a chemical, biological, radiological, nuclear, and explosives (CBRNE) command at the theater level. This ATP provides the foundation forthe CBRNE command doctrine and focuses on organization, mission, and command and control (C2). It discusses employment concepts, planning
Chemical, biological, radiological and nuclear CBRN ...
assets.publishing.service.gov.ukChemical biological radiological and nuclear incidents handbook 3 Chemical, biological, radiological and nuclear incidents: clinical management and health protection Gent N, & Milton R, editors. CRBN incidents: clinical management & health protection. 2nd ed. London: Public Health England; 2018. PHE Publications gateway number 2018080
Biological Reactors (Chemostat) - MIT OpenCourseWare
ocw.mit.edu10.37 Chemical and Biological Reaction Engineering, Spring 2007 Prof. K. Dane Wittrup Lecture 13: Biological Reactors- Chemostats This lecture covers: theory of the chemostat, fed batch or semi-continuous fermentor
National Organic Program Handbook : Guidance and ...
www.ams.usda.govCertification of Operations Based in Canada N/A 3/19/2012 Criteria and Qualifications for Organic Inspectors N/A 4/27/2012 Exporting European Union Organic Products to the United States N/A 5/25/2012 Exporting USDA Organic Products to the European Union N/A 5/25/2012 Sodium Nitrate Use in Organic Crop Production Notice 12-1 9/11/2012